W. George Lai, Ph.D., is currently Senior Director and Head of Translational ADME & PK/PD at Schrödinger Inc. With 20 years of experience in the pharmaceutical industry, he is an expert in optimization and characterization of DMPK properties throughout the course of drug discovery, development and clinical trial. He most recently served as Senior Director and Head of DMPK at Eisai, Inc. In this role, he led a team that successfully completed high-quality regulatory submission packages for at least ten diverse clinical candidates for immunology, oncology, and neurology indications. In an earlier role at Eisai, Dr. Lai made translational ADME and bioanalytical contributions that helped ensure the successful development of HALAVEN® (eribulin mesylate) from preclinical to clinical stages. Prior to joining Eisai, Dr. Lai worked as a Principal Scientist at Boehringer Ingelheim. He holds a Ph.D. in pharmaceutical science from the University of Toronto.
Tuesday, January 28, 2020
8:00 AM – 9:15 AM